Liftstream is an executive search recruitment company in the life sciences sector
Celgene and BMS team up for cancer immunotherapy development
Authored by James Sheppard
Pfizer and Merck collaborate for cancer immunotherapy
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Amgen, big pharma, BioRN, BMS, Boston Biotech, celgene, immunotherapy, Lung Cancer, Merck, Munich Biotech, oncology, pembrolizumab, Pfizer, Xalkori
Leave a comment
Symphogen’s Monoclonal Antibody Technology Making Waves
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, antibody drug conjugate, clinical trials, conjugated mAb, epidermal growth factor receptor, Essex Woodland, European Society of Hematology, Genentech, hematology, Kirsten Drejer, Medicon Valley, Merck, monoclonal antibody, Novo A/S, oncology, Phase II, PKA, Roche, squamous cell carcinoma of the head & neck, SYM004, Symphogen
Leave a comment
Biogen & Amicus partner for new Parkinson’s Drug Hunt
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged A2A agonists, Amicus Therapeutics, AstraZeneca, Biogen IDEC, BMS, Bristol-Myers Squibb, Isis Pharmaceuticals, John Crowley, Merck, multiple neurological targets, neurodegenerative, Parkinson’s disease, Tufts University, Vanderblit Center for Neurodegenerative Drug Discovery
Leave a comment
Roche scores conditional European win with Erivedge
Authored by Karl Simpson
Posted in Pharmaceutical business
Tagged antibody, ASCO, basal cell carcinoma, BCC, BMS, CHMP, Conditional approval, conditional marketing authorization, CUDC-907, Curis Inc, EMA, Erivedge, europe, European Commission, Genentech, HDAC inhibitor, IAP proteins, immunotherapy, Melanoma, Merck, MPDL3280A, oncolgy, PD-1, PI3K, Roche, vismodegib
Leave a comment
Amgen feeling positive over melanoma drug
Authored by James Sheppard
Posted in Pharmaceutical business
Tagged Amgen, BMS, cancer, combination, GM-CSF, Howard Kaufman, immunotherapy, investigator, lambrolizumab, Melanoma, Merck, nivolumab, oncology, oncolytic immunotherapy, Paracetamol, Phase III, Sean Harper, Tylenol
Leave a comment
Avastin disappoints in study for treatment of Brain Cancer
Authored by Karl Simpson
Posted in Pharmaceutical business
Tagged Avastin, brain cancer, chemo, clinical development, FDA, Glioblastoma, Houston, MD Anderson Cancer Center, Merck, oncology, PFS, Roche, temador, USA
Leave a comment
Sanofi Suffers Setback with two drugs
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged biPar Science, blockbuster, breast cancer, competitor, development program, ECLIPSE, Factor Xa inhibitor, failure, iniparib, Integrillin, Merck, non-small cell lung cancer, NSCLC, oncology, otamixaban, ovarian cancer, Sanofi, TAO results
Leave a comment
Endocyte diagnoses companion in Merck to set precedent!
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged BioRN, cancer, companion diagnostics, diagnostics, ECo652, EMA, Endocyte, etarfolatide, EU, European Commission, FDA, folate-receptor positive, IND, Merck, non-small cell lung cancer, oncology, Orphan Drug Congress, ovarian cancer, PRECEDENT, PROCEED, PSMA, Ron Ellis, small-molecule drug conjugates, vintafolide, viral infections
Leave a comment
PTC Therapeutics opts for conditional approach in Duchenne
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged Allan Jacobson, AstraZeneca, Ataluren, celgene, Cystic Fibrosis, DMD, DNA, Duchenne Muscular Dystrophy, EMA, FDA, Genzyme, Gilead, Liftstream Rare Disease Day, MAA, Marketing Authorisation Application, Merck, Orphan Drug, Pfizer, PTC Therapeutics, Rare Disease, rare disease day, RDD13, Stuart W. Peltz
Leave a comment